Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Inetetamab|DRUG: Pyrotinib|DRUG: Vinorelbine
Sponsor: The First Affiliated Hospital with Nanjing Medical University